關於 Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy is currently in Phase 2 clinical trial.
Source: Wikipedia
產業Biotechnology
總部Hayward, CA
成立時間2004
法律形式C Corporation
狀態營運中
專利1 項專利
PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPASE INHIBITOR SODIUM [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL]OX…JP2011021042A · 2011
關鍵數據
法律資訊
| 法定名稱 | Anthera Pharmaceuticals Inc |
|---|---|
| 法律形式 | C Corporation |
| SEC CIK | 1316175在 SEC EDGAR 上查看 ↗ |
| 登記地址 | Hayward, CA |
| 狀態 | 營運中 |
來源: SEC EDGAR · 更新於 2026年11月14日